Expression of salivary biomarkers in patients with oral mucositis: Evaluation by SELDI-TOF/MS

Oral Diseases

Volumn 22, Issue 3, 2016, Pages 209-219

  Ardito, F ^a   Giuliani, M ^a   Perrone, D ^a   Giannatempo, G ^a   Di Fede, O ^b   Favia, G ^c   Campisi, G ^b   Colella, G ^d   Lo Muzio, L ^a  

^a UNIVERSITY OF FOGGIA   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

^c UNIVERSITY OF BARI   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Biomarker discovery; Oral mucositis; Saliva; SELDI TOF MS

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; TRASTUZUMAB;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; EVALUATION STUDY; FEMALE; HUMAN; MALE; ORAL MUCOSITIS; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; SALIVA ANALYSIS; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; ADJUVANT CHEMOTHERAPY; ADJUVANT RADIOTHERAPY; ADVERSE EFFECTS; CHEMISTRY; MATRIX-ASSISTED LASER DESORPTION-IONIZATION MASS SPECTROMETRY; METABOLISM; MIDDLE AGED; NEOPLASMS; RADIATION INJURIES; SALIVA; STOMATITIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; RADIATION INJURIES; RADIOTHERAPY, ADJUVANT; SALIVA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STOMATITIS;

EID: 84975781062     PISSN: 1354523X     EISSN: 16010825     Source Type: Journal    
DOI: 10.1111/odi.12405     Document Type: Article

References (37)

1. Al-Dasooqi N, Gibson RJ, Bowen JM, Logan RM, Stringer AM, Keefe DM (2010). Matrix metalloproteinases are possible mediators for the development of alimentary tract mucositis in the dark agouti rat. Exp Biol Med 235: 1244-1256.
2. Al-Dasooqi N, Sonis ST, Bowen JM et al (2013). Emerging evidence on the pathobiology of mucositis. Support Care Cancer 21: 3233-3241.
3. Barber C, Powell R, Ellis A, Hewett J (2007). Comparing pain control and ability to eat and drink with standard therapy vs Gelclair: a preliminary, double centre, randomised controlled trial on patients with radiotherapy-induced oral mucositis. Supportive Care Cancer 15: 427-440.
4. Bigler LR, Streckfus CF, Copeland L et al (2002). The potential use of saliva to detect recurrence of disease in women with breast carcinoma. J Oral Pathol Med 31: 421-431.
5. Bigler LR, Streckfus CF, Dubinsky WP (2009). Salivary biomarkers for the detection of malignant tumors that are remote from the oral cavity. Clin Lab Med 29: 71-85.
6. Campos MI, Campos CN, Aarestrup FM, Aarestrup BJ (2014). Oral mucositis in cancer treatment: Natural history, prevention and treatment. Mol Clin Oncol 2: 337-340.
7. Cheng KK, Molassiotis A, Chang AM, Wai WC, Cheung SS (2001). Evaluation of an oral care protocol intervention in the prevention of chemotherapy-induced oral mucositis in paediatric cancer patients. Eur J Cancer 37: 2056-2063.
8. Hansen RM, Ryan L, Anderson T et al (1996). Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst 88: 668-674.
9. Hu S, Loo JA, Wong DT (2007a). Human saliva proteome analysis and disease biomarker discovery. Expert Rev Proteomics 4: 531-538.
10. Hu S, Wang J, Meijer J et al (2007b). Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome. Arthritis Rheum 56: 3588-3600.
11. Hu S, Yen Y, Ann D, Wong DT (2007c). Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery. Drug Discov Today 12: 911-916.
12. Hu S, Arellano M, Boontheung P et al (2008). Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res 14: 6246-6252.
13. Kaufman E, Lamster IB (2002). The diagnostic applications of saliva - a review. Crit Rev Oral Biol Med 13: 197-212.
14. Li Y, St John MA, Zhou X et al (2004). Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 10: 8442-8450.
15. Logan RM, Stringer AM, Bowen JM et al (2007). The role of pro-inflammatory cytokines in cancer treatment-induced alimentary tract mucositis: pathobiology, animal models and cytotoxic drugs. Cancer Treat Rev 33: 448-460.
16. McGuire DB (2002). Mucosal tissue injury in cancer therapy. More than muscositis and mouthwash. Cancer Pract 10: 179-191.
17. McGuire DB, Fulton JS, Park J et al (2013). Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer 21: 3165-3177.
18. Migliorati C, Hewson I, Lalla RV et al (2013). Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer 21: 333-341.
19. Park NJ, Zhou H, Elashoff D et al (2009). Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 15: 5473-5477.
20. Peterson DE, Bensadoun RJ, Roila F and Group EGW (2011). Management of oral and gastrointestinal mucositis: ESMO Clinical Practice Guidelines. Ann Oncol 22(Suppl 6): vi78-vi84.
21. Peterson DE, Ohrn K, Bowen J et al (2013). Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer 21: 327-332.
22. Raber-Durlacher JE, Weijl NI, Abu Saris M, de Koning B, Zwinderman AH, Osanto S (2000). Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer 8: 366-371.
23. Raber-Durlacher JE, vonBultzingslowen I, Logan RM et al (2013). Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients. Support Care Cancer 21: 343-355.
24. Roopashri G, Jayanthi K, Guruprasad R (2011). Efficacy of benzydamine hydrochloride, chlorhexidine, and povidone iodine in the treatment of oral mucositis among patients undergoing radiotherapy in head and neck malignancies: a drug trail. Contemp Clin Dent 2: 8-12.
25. Sloan JA, Loprinzi CL, Novotny PJ, Okuno S, Nair S, Barton DL (2000). Sex differences in fluorouracil-induced stomatitis. J Clin Oncol 18: 412-420.
26. Sloan JA, Goldberg RM, Sargent DJ et al (2002). Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 20: 1491-1498.
27. Sonis ST (2004). Pathobiology of mucositis. Semin Oncol Nurs 20: 11-15.
28. Sonis ST (2009). Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis. Core Evid 4: 199-205.
29. Sonis ST, Fey EG (2002). Oral complications of cancer therapy. Oncology, 69: 680-686; discussion 686, 691-2, 695.
30. Steinmann D, Eilers V, Beynenson D, Buhck H, Fink M (2012). Effect of Traumeel S on pain and discomfort in radiation-induced oral mucositis: a preliminary observational study. Altern Ther Health Med 18: 12-18.
31. Stiff P (2001). Mucositis associated with stem cell transplantation: current status and innovative approaches to management. Bone Marrow Transplant 27(Suppl 2): S3-S11.
32. Streckfus CF, Bigler LR (2002). Saliva as a diagnostic fluid. Oral Dis 8: 69-76.
33. Streckfus CF, Bigler LR, Zwick M (2006). The use of surface-enhanced laser desorption/ionization time-of-flight mass spectrometry to detect putative breast cancer markers in saliva: a feasibility study. J Oral Pathol Med 35: 292-300.
34. Worthington HV, Clarkson JE, Eden OB (2007). Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev CD000978.
35. Xiao H, Wong DT (2010). Proteomics and its applications for biomarker discovery in human saliva. Bioinformation 5: 294-296.
36. Zhang L, Farrell JJ, Zhou H et al (2010a). Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 138: 949-957 e1-7.
37. Zhang L, Xiao H, Karlan S et al (2010b). Discovery and preclinical validation of salivary transcriptomic and proteomic biomarkers for the non-invasive detection of breast cancer. PLoS One 5: e15573.